In a filing, Taysha Gene Therapies Inc revealed its 10% Owner Manning Paul B acquired Company’s shares for reported $3.0 million on Jun 27 ’24. In the deal valued at $2.25 per share,1,333,333 shares were bought. As a result of this transaction, Manning Paul B now holds 1,333,333 shares worth roughly $3.09 million.
BMO Capital Markets initiated its Taysha Gene Therapies Inc [TSHA] rating to an Outperform in a research note published on June 27, 2024; the price target was $5. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early April with a ‘”an Overweight”‘ rating. Jefferies also remained covering TSHA and has decreased its forecast on February 01, 2023 with a “Hold” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 27, 2023. It rated TSHA as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of TSHA
On Monday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock jump 8.92% to $2.32. Over the last five days, the stock has lost -5.69%. Taysha Gene Therapies Inc shares have risen nearly 34.10% since the year began. Nevertheless, the stocks have fallen -2.52% over the past one year. While a 52-week high of $4.32 was reached on 05/02/25, a 52-week low of $1.05 was recorded on 04/09/25. SMA at 50 days reached $1.69, while 200 days put it at $1.92.
Levels Of Support And Resistance For TSHA Stock
The 24-hour chart illustrates a support level at 2.20, which if violated will result in even more drops to 2.07. On the upside, there is a resistance level at 2.39. A further resistance level may holdings at 2.46. The Relative Strength Index (RSI) on the 14-day chart is 62.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.51%. Stochastics %K at 57.31% indicates the stock is a holding.
